Affordable Access

deepdyve-link
Publisher Website

Metronomic Maintenance Therapy for Rhabdomyosarcoma.

Authors
  • André, Nicolas1
  • Corradini, Nadège2
  • Shaked, Yuval3
  • 1 Pediatric Hematology and Oncology Department, Hôpital pour Enfant de La Timone, Assistance Publique - Hôpitaux de Marseille (AP-HM), Marseille, France; SMARTc unit, Centre de Recherche en Cancérologie de Marseille, Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 1068, Université d'Aix-Marseille, Marseille, France; Metronomics Global Health Initiative, Marseille, France. Electronic address: [email protected] , (France)
  • 2 Institut d'Hématologie et Oncologie Pédiatrique, Lyon, France. , (France)
  • 3 Metronomics Global Health Initiative, Marseille, France; Faculty of Medicine, Cell Biology, and Cancer Science, Technion-Integrated Cancer Center, Technion, Israel Institute of Technology, Haifa, Israel. , (France)
Type
Published Article
Journal
Trends in cancer
Publication Date
Dec 01, 2019
Volume
5
Issue
12
Pages
756–759
Identifiers
DOI: 10.1016/j.trecan.2019.10.004
PMID: 31813450
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

In a recent article, Bisogno et al. reported in a randomized trial that addition of metronomic maintenance therapy (MMT) with vinorelbine plus cyclophosphamide for children with rhabdomyosarcoma resulted in a significant increase in overall and event-free survival. Although the mechanism of action remains to be fully elucidated, this study paves the way for further evaluation of MMT as a potential therapeutic strategy in pediatric patients with high-risk disease. Copyright © 2019 Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times